Rockefeller Capital Management’s Aberdeen India Fund IFN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-932
Closed -$13.7K 4751
2025
Q3
$13.7K Buy
+932
New +$14.4K ﹤0.01% 3534
2023
Q1
Sell
-18
Closed 2888
2022
Q4
$0 Sell
18
-1,200
-99% -$19.2K ﹤0.01% 4025
2022
Q3
$19K Buy
1,218
+1
+0.1% +$17 ﹤0.01% 2797
2022
Q2
$19K Sell
1,217
-519
-30% -$9.16K ﹤0.01% 2775
2022
Q1
$33K Buy
1,736
+48
+3% +$967 ﹤0.01% 2500
2021
Q4
$35K Hold
1,688
﹤0.01% 2366
2021
Q3
$38K Sell
1,688
-1,304
-44% -$29.4K ﹤0.01% 2271
2021
Q2
$65K Sell
2,992
-750
-20% -$16K ﹤0.01% 1961
2021
Q1
$80K Sell
3,742
-646
-15% -$13.5K ﹤0.01% 1701
2020
Q4
$87K Sell
4,388
-1,642
-27% -$29.8K ﹤0.01% 1497
2020
Q3
$99K Sell
6,030
-318
-5% -$5.22K ﹤0.01% 1261
2020
Q2
$98K Buy
6,348
+5,931
+1,422% +$86K ﹤0.01% 1171
2020
Q1
$6K Buy
+417
New +$7.69K ﹤0.01% 1894
2019
Q4
Sell
-395
Closed -$8K 2122
2019
Q3
$8K Hold
395
﹤0.01% 1489
2019
Q2
$8K Buy
+395
New +$8.43K ﹤0.01% 1316

Other funds holding IFN

Rockefeller Capital Management's IFN Position: Q4 2025 in Review

Rockefeller Capital Management sold out of Aberdeen India Fund (IFN) in Q4 2025, closing a stake of 932 shares — an estimated $13.7K sold.

Rockefeller Capital Management first reported a position in IFN in Q2 2019 and held it in 15 quarters. The position peaked at $99K in Q3 2020. 72 funds tracked by Wall St. Rank hold IFN as of Q4 2025.

  • Rockefeller Capital Management reported no remaining Aberdeen India Fund position as of Q4 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 932 Aberdeen India Fund shares in Q4 2025, an estimated $13.7K.
  • Rockefeller Capital Management first reported a position in Aberdeen India Fund in Q2 2019 and held it in 15 quarters.
  • Rockefeller Capital Management's Aberdeen India Fund position peaked at $99K in Q3 2020.
  • 72 funds tracked by Wall St. Rank held Aberdeen India Fund as of Q4 2025.

Based on Rockefeller Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.